| 2025 |
| 04/04 | 1,301 | 1,330 | 1,266 | 1,305 | -3.26% | 389,700 | 543億3028万 | -11.47% |
| 04/03 | 1,332 | 1,357 | 1,317 | 1,349 | -3.71% | 310,700 | 561億6210万 | -9.04% |
| 04/02 | 1,431 | 1,438 | 1,393 | 1,401 | -2.1% | 151,600 | 583億2699万 | -5.91% |
| 04/01 | 1,450 | 1,464 | 1,429 | 1,431 | 0% | 136,200 | 595億7596万 | -4.22% |
| 03/31 | 1,445 | 1,449 | 1,425 | 1,431 | -2.98% | 180,200 | 595億7596万 | -4.54% |
| 03/28 | 1,502 | 1,522 | 1,465 | 1,475 | -2.96% | 192,900 | 614億779万 | -1.99% |
| 03/27 | 1,511 | 1,520 | 1,504 | 1,520 | +0.33% | 167,200 | 632億8124万 | +0.66% |
| 03/26 | 1,510 | 1,533 | 1,502 | 1,515 | +0.13% | 125,500 | 630億7308万 | +0.07% |
| 03/25 | 12:30 代表取締役の異動および役員人事について |
| 03/25 | 1,519 | 1,522 | 1,506 | 1,513 | -0.26% | 90,100 | 629億8982万 | -0.46% |
| 03/24 | 11:30 米国神経学会（AAN）にて当社子会社SNLD社がパーキンソン病の点鼻レボドパ薬の臨床試験成績を発表 |
| 03/24 | 1,539 | 1,539 | 1,505 | 1,517 | -1.43% | 186,500 | 631億5635万 | -0.46% |
| 03/21 | 1,541 | 1,552 | 1,525 | 1,539 | -0.77% | 129,300 | 640億7226万 | +0.46% |
| 03/19 | 1,565 | 1,570 | 1,546 | 1,551 | -0.96% | 124,300 | 645億7185万 | +0.71% |
| 03/18 | 1,575 | 1,577 | 1,551 | 1,566 | 0% | 148,100 | 651億9633万 | +1.16% |
| 03/17 | 1,540 | 1,571 | 1,540 | 1,566 | +1.75% | 190,500 | 651億9633万 | +0.58% |
| 03/14 | 1,520 | 1,548 | 1,516 | 1,539 | +0.72% | 228,900 | 640億7226万 | -1.85% |
| 03/13 | 1,522 | 1,565 | 1,517 | 1,528 | +0.73% | 355,700 | 636億1430万 | -3.17% |
| 03/12 | 1,439 | 1,527 | 1,439 | 1,517 | +5.27% | 426,200 | 631億5635万 | -4.17% |
| 03/11 | 1,466 | 1,470 | 1,420 | 1,441 | -3.35% | 332,300 | 599億9228万 | -9.26% |
| 03/10 | 1,491 | 1,520 | 1,466 | 1,491 | +2.05% | 486,400 | 620億7390万 | -6.75% |
| 03/07 | 1,449 | 1,511 | 1,413 | 1,461 | +5.18% | 872,400 | 608億2493万 | -9.09% |
| 03/06 | 1,420 | 1,423 | 1,386 | 1,389 | -1.77% | 320,600 | 578億2740万 | -14.05% |
| 03/05 | 1,425 | 1,435 | 1,407 | 1,414 | -0.63% | 223,100 | 588億6821万 | -13.14% |
| 03/04 | 1,468 | 1,471 | 1,412 | 1,423 | -4.43% | 330,100 | 592億4290万 | -13.18% |
| 03/03 | 1,512 | 1,516 | 1,476 | 1,489 | +0.27% | 152,100 | 619億9064万 | -9.65% |
| 02/28 | 1,498 | 1,516 | 1,474 | 1,485 | -1.92% | 222,700 | 618億2411万 | -10.27% |
| 02/27 | 1,505 | 1,545 | 1,491 | 1,514 | +0.53% | 270,200 | 630億3145万 | -8.9% |
| 02/26 | 1,530 | 1,536 | 1,481 | 1,506 | -1.76% | 295,500 | 626億9839万 | -9.77% |
| 02/25 | 1,534 | 1,570 | 1,533 | 1,533 | -1.22% | 147,500 | 638億2246万 | -8.42% |
| 02/21 | 1,541 | 1,570 | 1,535 | 1,552 | -1.27% | 181,000 | 646億1348万 | -7.56% |
| 02/20 | 1,590 | 1,601 | 1,564 | 1,572 | -2% | 227,900 | 654億4613万 | -6.54% |
| 02/19 | 1,630 | 1,636 | 1,598 | 1,604 | -0.99% | 337,000 | 667億7836万 | -4.75% |
| 02/18 | 1,668 | 1,668 | 1,618 | 1,620 | -2.41% | 232,300 | 674億4448万 | -4.03% |
| 02/17 | 1,575 | 1,665 | 1,551 | 1,660 | +2.79% | 543,000 | 691億978万 | -1.78% |
| 02/14 | 1,700 | 1,717 | 1,615 | 1,615 | -6.43% | 588,800 | 672億3632万 | -4.44% |
| 02/13 | 1,750 | 1,752 | 1,725 | 1,726 | -0.23% | 260,100 | 718億5752万 | +1.95% |
| 02/12 | 1,756 | 1,761 | 1,727 | 1,730 | -1.87% | 324,200 | 720億2405万 | +2.37% |
| 02/10 | 1,735 | 1,774 | 1,725 | 1,763 | -0.68% | 375,300 | 733億9792万 | +4.63% |
| 02/07 | 13:00 CDP2024の「気候変動」で「Bスコア」、「水セキュリティ」で「B-スコア」を獲得しました |
| 02/07 | 1,836 | 1,857 | 1,767 | 1,775 | -4.52% | 504,700 | 738億9751万 | +5.59% |
| 02/06 | 1,853 | 1,897 | 1,801 | 1,859 | +4.85% | 1,131,900 | 773億9463万 | +10.79% |
| 02/05 | 11:30 2025年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/05 | 11:30 2025年3月期通期連結業績予想の修正に関するお知らせ |
| 02/05 | 11:30 2025年3月期第3四半期決算説明資料(決算説明会資料) |
| 02/05 | 1,635 | 1,828 | 1,575 | 1,773 | +7.13% | 1,655,900 | 738億1424万 | +6.1% |
| 02/04 | 1,661 | 1,669 | 1,637 | 1,655 | -0.36% | 213,200 | 689億162万 | -0.78% |
| 02/03 | 1,692 | 1,692 | 1,645 | 1,661 | -2.29% | 212,900 | 691億5141万 | -0.54% |
| 01/31 | 1,690 | 1,700 | 1,680 | 1,700 | +0.06% | 105,500 | 707億7508万 | +1.74% |
| 01/30 | 1,675 | 1,703 | 1,670 | 1,699 | +1.55% | 161,700 | 707億3344万 | +1.92% |
| 01/29 | 1,696 | 1,706 | 1,673 | 1,673 | -1.88% | 147,000 | 696億5100万 | +0.72% |
| 01/28 | 1,683 | 1,715 | 1,683 | 1,705 | +1.31% | 256,200 | 709億8324万 | +2.96% |
| 01/27 | 1,670 | 1,713 | 1,659 | 1,683 | +1.45% | 323,000 | 700億6732万 | +2.06% |
| 01/24 | 1,645 | 1,684 | 1,634 | 1,659 | +0.79% | 190,300 | 690億6815万 | +0.85% |
| 01/23 | 1,659 | 1,664 | 1,629 | 1,646 | -1.67% | 175,600 | 685億2693万 | +0.24% |
| 01/22 | 1,691 | 1,698 | 1,667 | 1,674 | -0.65% | 124,800 | 696億9263万 | +2.14% |
| 01/21 | 1,631 | 1,705 | 1,626 | 1,685 | +3.25% | 258,200 | 701億5059万 | +3% |
| 01/20 | 1,659 | 1,669 | 1,629 | 1,632 | -0.61% | 223,800 | 679億4407万 | 0% |
| 01/17 | 1,640 | 1,650 | 1,604 | 1,642 | +0.61% | 194,500 | 683億6040万 | +0.74% |
| 01/16 | 1,655 | 1,667 | 1,627 | 1,632 | -0.55% | 133,200 | 679億4407万 | +0.25% |
| 01/15 | 1,688 | 1,692 | 1,626 | 1,641 | -3.7% | 266,400 | 683億1876万 | +0.92% |
| 01/14 | 15:30 ESG 投資指数「FTSE Blossom Japan Sector Relative Index」の構成銘柄に継続選定されました |
| 01/14 | 1,660 | 1,714 | 1,660 | 1,704 | +2.1% | 321,700 | 709億4160万 | +5.06% |
| 01/10 | 1,650 | 1,674 | 1,637 | 1,669 | +1.09% | 119,000 | 694億8447万 | +3.15% |
| 01/09 | 1,689 | 1,692 | 1,644 | 1,651 | -1.67% | 151,800 | 687億3509万 | +2.17% |
| 01/08 | 1,671 | 1,693 | 1,657 | 1,679 | +1.21% | 203,400 | 699億79万 | +4.03% |
| 01/07 | 1,640 | 1,672 | 1,623 | 1,659 | +2.92% | 253,700 | 690億6815万 | +3.11% |
| 01/06 | 1,684 | 1,684 | 1,604 | 1,612 | -3.36% | 251,800 | 671億1142万 | +0.5% |
| 01/06 | 8:30 2025年（令和7年）元旦 新年の挨拶 |
| 2024 |
| 12/30 | 1,696 | 1,696 | 1,658 | 1,668 | -1.65% | 219,200 | 694億4284万 | +4.12% |
| 12/27 | 1,704 | 1,709 | 1,686 | 1,696 | +0.53% | 187,600 | 706億855万 | +6.27% |
| 12/26 | 1,677 | 1,698 | 1,668 | 1,687 | +0.6% | 190,800 | 702億3385万 | +6.23% |
| 12/25 | 1,720 | 1,730 | 1,664 | 1,677 | -2.73% | 311,700 | 698億1753万 | +6.07% |
| 12/24 | 1,680 | 1,725 | 1,673 | 1,724 | +2.74% | 468,000 | 717億7425万 | +9.67% |
| 12/23 | 1,650 | 1,710 | 1,648 | 1,678 | +4.61% | 740,200 | 698億5916万 | +7.56% |
| 12/20 | 1,650 | 1,686 | 1,596 | 1,604 | +4.43% | 918,200 | 667億7836万 | +3.48% |
| 12/19 | 1,535 | 1,543 | 1,525 | 1,536 | -1.29% | 134,600 | 639億4736万 | -0.45% |
| 12/18 | 1,538 | 1,580 | 1,538 | 1,556 | +1.17% | 162,000 | 647億8001万 | +0.97% |
| 12/17 | 1,553 | 1,553 | 1,512 | 1,538 | -1.91% | 266,000 | 640億3063万 | +0.07% |
| 12/16 | 1,585 | 1,593 | 1,567 | 1,568 | -0.82% | 121,300 | 652億7960万 | +2.15% |
| 12/13 | 1,579 | 1,593 | 1,567 | 1,581 | -0.75% | 178,400 | 658億2082万 | +3.2% |
| 12/12 | 1,595 | 1,604 | 1,575 | 1,593 | -0.06% | 233,800 | 663億2041万 | +4.39% |
| 12/11 | 1,591 | 1,608 | 1,573 | 1,594 | +0.95% | 211,700 | 663億6204万 | +4.8% |
| 12/10 | 1,594 | 1,594 | 1,567 | 1,579 | -0.94% | 233,600 | 657億3755万 | +4.5% |
| 12/09 | 1,595 | 1,608 | 1,582 | 1,594 | +0.82% | 247,100 | 663億6204万 | +6.48% |
| 12/06 | 1,590 | 1,599 | 1,564 | 1,581 | +0.51% | 195,600 | 658億2082万 | +6.68% |
| 12/05 | 1,551 | 1,584 | 1,540 | 1,573 | +1.55% | 215,400 | 654億8776万 | +7.08% |
| 12/04 | 1,600 | 1,600 | 1,515 | 1,549 | -3.19% | 366,200 | 644億8858万 | +6.39% |
| 12/03 | 1,605 | 1,615 | 1,593 | 1,600 | -1.05% | 273,800 | 666億1184万 | +10.8% |
| 12/02 | 1,593 | 1,625 | 1,582 | 1,617 | +1.25% | 482,200 | 673億1959万 | +13.16% |
| 11/29 | 1,550 | 1,602 | 1,542 | 1,597 | +2.77% | 518,600 | 664億8694万 | +13.02% |
| 11/28 | 1,560 | 1,564 | 1,541 | 1,554 | -0.06% | 278,500 | 646億9674万 | +11.08% |
| 11/27 | 1,543 | 1,560 | 1,527 | 1,555 | +0.06% | 283,500 | 647億3838万 | +12.11% |
| 11/26 | 1,525 | 1,559 | 1,515 | 1,554 | +2.3% | 442,600 | 646億9674万 | +13.02% |
| 11/26 | 8:30 Satsuma社の経鼻偏頭痛薬STS101の米国FDAによる新薬承認再申請受理について |
| 11/25 | 1,525 | 1,542 | 1,515 | 1,519 | +1.47% | 354,700 | 632億3961万 | +11.36% |
| 11/22 | 1,540 | 1,547 | 1,466 | 1,497 | -0.33% | 436,000 | 623億2370万 | +10.48% |
| 11/21 | 1,464 | 1,509 | 1,446 | 1,502 | +3.59% | 463,800 | 625億3186万 | +11.59% |
| 11/20 | 1,458 | 1,472 | 1,441 | 1,450 | +1.54% | 307,400 | 603億6698万 | +8.61% |
| 11/19 | 1,424 | 1,445 | 1,412 | 1,428 | +0.56% | 241,900 | 594億5106万 | +7.69% |
| 11/18 | 1,422 | 1,445 | 1,414 | 1,420 | -1.46% | 227,800 | 591億1800万 | +7.82% |
| 11/15 | 1,479 | 1,482 | 1,438 | 1,441 | -2.31% | 307,300 | 599億9228万 | +10% |
| 11/14 | 1,477 | 1,489 | 1,458 | 1,475 | -0.2% | 339,400 | 614億779万 | +13.29% |
| 11/13 | 1,470 | 1,489 | 1,464 | 1,478 | 0% | 348,100 | 615億3268万 | +14.31% |
| 11/12 | 1,490 | 1,500 | 1,475 | 1,478 | -0.81% | 371,300 | 615億3268万 | +15.02% |
| 11/11 | 1,444 | 1,500 | 1,444 | 1,490 | +4.63% | 615,700 | 620億3227万 | +16.86% |
| 11/08 | 1,458 | 1,458 | 1,418 | 1,424 | -3.13% | 663,000 | 592億8453万 | +12.48% |
| 11/07 | 1,383 | 1,476 | 1,382 | 1,470 | +9.05% | 1,276,100 | 611億9962万 | +16.85% |
| 11/06 | 11:30 2025年3月期上期決算説明資料 |
| 11/06 | 11:30 2025年3月期第2四半期決算短信〔日本基準〕(連結) |
| 11/06 | 11:30 2025年3月期第2四半期連結業績予想と実績との差異に関するお知らせ |
| 11/06 | 11:30 剰余金の配当(中間配当)に関するお知らせ |
| 11/06 | 1,259 | 1,378 | 1,253 | 1,348 | +8.62% | 920,400 | 561億2047万 | +8.01% |
| 10/31 | 8:30 Satsuma社の経鼻偏頭痛薬STS101の新薬承認再申請実施のお知らせ |
